The adoptive transfer of immunologically sensitized T lymphocytes can eradicate established malignancy in animal models. However, inconsistent results have been achieved in clinical trials of adoptive immunotherapy. The applicant has focused on the isolation of therapeutic T cells from the tumor-bearing host, as this has direct relevance for translation of adoptive immunotherapy to human clinical trials. T cells can be isolated from lymph nodes draining a progressively growing tumor that are able to mediate the regression of tumor upon adoptive transfer. Recently he has identified a population of CD4 T cells that can mediate the regression of an established MHC class II negative tumor. These CD4 T cells are more potent on a per cell basis at tumor eradication than previously isolated tumor-reactive T cells. The hypothesis is that CD4 T cells are potent antitumor effector cells. This is explored by studying the development, therapeutic reactivity, and effector mechanisms of tumor-reactive CD4 T cells, as this knowledge may provide for improvements in human adoptive immunotherapy.
Specific Aim 1 studies the therapeutic reactivity of CD4 L-selectin- T cells against brain, lung, and subcutaneous tumors, and studies the role of CD28 and CD40L interactions in the development of these CD4 T cells. The CD4 L-selectin-T cells that can eliminate tumor secrete IL-2, IFN-g, and IL-10 upon stimulation with tumor, and therefore may either not be fully differentiated (Th0), or may be a mixture of Thl and Th2 type cells. Therefore, Specific Aim 2 investigates the ability of cytokine differentiated CD4 T cells and CD4 T cell clones to eradicate tumor, to further define the T cell that is responsible for tumor elimination. In bulk cultured lymph node T cells, IFN-g is required for elimination of tumor in the lungs, while perforin is required for the elimination of subcutaneous tumor. The effector molecules used by CD4 T cells to eliminate tumor have not been elucidated, and the contribution of perforin, IFN-g, and FASL to tumor eradication by adaptively transferred CD4 T cells is investigated in Specific Aim 3.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA078263-01
Application #
2666474
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Hecht, Toby T
Project Start
1998-07-01
Project End
2002-04-30
Budget Start
1998-07-01
Budget End
1999-04-30
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Cleveland Clinic Lerner
Department
Type
DUNS #
017730458
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Tanaka, Hiroshi; Tanaka, Junta; Kjaergaard, Jorgen et al. (2002) Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 25:207-17
Peng, Liaomin; Kjaergaard, Jorgen; Plautz, Gregory E et al. (2002) Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy. J Immunol 169:4811-21
Kim, J A; Averbook, B J; Chambers, K et al. (2001) Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res 61:2031-7
Kjaergaard, J; Peng, L; Cohen, P A et al. (2001) Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J Immunol 167:6669-77
Peng, L; Krauss, J C; Plautz, G E et al. (2000) T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-gamma mechanisms that cannot be predicted from in vitro T cell characteristics. J Immunol 165:7116-24
Kjaergaard, J; Tanaka, J; Kim, J A et al. (2000) Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res 60:5514-21
Peng, L; Kjaergaard, J; Plautz, G E et al. (2000) Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression. J Immunol 165:5738-49
Kjaergaard, J; Shu, S (1999) Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression. J Immunol 163:751-9